Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has released its Corporate Governance Statement for the financial year ending June 2025, outlining its adherence to the ASX Corporate Governance Principles and Recommendations. The statement highlights the company’s commitment to ethical practices, board performance, diversity, and risk management, which are crucial for its strategic direction and stakeholder trust.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the medical technology industry, focusing on the development of radiopharmaceutical products. The company is committed to maintaining high standards of ethics, integrity, and statutory compliance in all its dealings.
Average Trading Volume: 3,509,371
Technical Sentiment Signal: Hold
Current Market Cap: A$73.31M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.